Bayer says FDA panel confirms safety of Aleve

02/24/2005 | iWon

Bayer said the recent judgment by an FDA advisory panel confirms the safety of the company's painkiller Aleve, distinguishing the safety profile of the drug's major ingredient, naproxen, from selective Cox-2 inhibitors and nonselective and nonsteroidal anti-inflammatory drugs. The company also noted an Alzheimer's trial was halted last December because of "administrative and practical" issues and not because of Aleve.

View Full Article in:

iWon

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ